Xeris CEO John Shannon named Board chair, adds new director Kreher

Xeris Biopharma Holdings announced that its Board of Directors appointed John Shannon to Chair of the Board, in addition to his role as Chief Executive Officer, effective July 1, 2026.¹ Shannon succeeds Marla Persky, who will remain on the Board as Lead Independent Director.¹

The company also said it appointed Nerissa Kreher, M.D., to its Board of Directors, effective July 1, 2026, expanding the Board to eight members.¹ Per the 8-K, the Board increased its size from seven to eight members on June 29, 2026, creating a vacancy filled by Kreher, who will serve as a Class III director with a term expiring at the 2027 annual meeting.¹ She has not yet been appointed to any Board committees.¹

Kreher's background includes serving since January 2025 as Chief Medical Officer of Alltrna, an RNA (tRNA) platform company.¹ Earlier roles included Chief Medical Officer of Entrada Therapeutics, a publicly traded biotechnology company, where she served from December 2020 to February 2024.¹ Before that, she held CMO posts at Tiburio Therapeutics from March 2019 to December 2020 and at AVROBIO, later acquired by Tectonic Therapeutics, from October 2016 to December 2018, where her work involved overseeing gene therapy clinical development.¹ She has also been an independent board member of Rezolute, Inc., a publicly traded biotechnology company, since March 2021.¹

The filing states there was no arrangement or family relationship behind her selection, and the Board determined she qualifies as independent under Nasdaq standards.¹ As compensation, Kreher received an initial equity grant of stock options and restricted stock units with a combined grant-date fair value of about $450,000 under the company's non-employee director compensation program.¹ Those awards vest over three equal annual installments, while future annual grants vest on the earlier of one year from grant or the next annual meeting.¹